Harvard Bioscience (HBIO) Cash from Investing Activities (2010 - 2026)
Harvard Bioscience (HBIO) reported Cash from Investing Activities of -$620000.0 for Q1 2026, up 9.22% year-over-year from -$567640.8 in Q1 2025, and down 3.51% quarter-over-quarter from -$599000.0 in Q4 2025.
Harvard Bioscience (HBIO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Cash from Investing Activities data on file, last reported at -$620000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$620000.0, up 9.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.8 million (changed 0.11% YoY), and the FY2025 annual result was -$1.9 million, down 38.62% from the prior year.
- Cash from Investing Activities declined to -$620000.0 in Q1 2026 per HBIO's latest filing, from -$599000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $458000.0 in Q2 2024 and troughed at -$1.1 million in Q3 2024.
- A 5-year average of -$424470.6 and a median of -$442000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 351.49% in 2023, then surged 173.28% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$235000.0 in 2022, then plunged by 351.49% to -$1.1 million in 2023, then jumped by 56.08% to -$466000.0 in 2024, then slipped by 28.54% to -$599000.0 in 2025, then dropped by 3.51% to -$620000.0 in 2026.
- Business Quant data shows HBIO's Cash from Investing Activities at -$620000.0 in Q1 2026, -$599000.0 in Q4 2025, and -$348000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -914.50 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -139.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -96.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -58.03 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -42.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -77.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -90.00 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -131.58 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -133.00 Mn |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | -620,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -620,000.00 |
| Mar 31, 2026 | -620,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Sep 30, 2025 | -348,000.00 |
| Sep 30, 2025 | -348,000.00 |
| Jun 30, 2025 | -233,000.00 |
| Jun 30, 2025 | -233,000.00 |
| Mar 31, 2025 | -683,000.00 |
| Mar 31, 2025 | -683,000.00 |
| Dec 31, 2024 | -466,000.00 |
| Dec 31, 2024 | -466,000.00 |
| Sep 30, 2024 | -1.11 Mn |
| Sep 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 458,000.00 |
| Mar 31, 2024 | -225,000.00 |
| Mar 31, 2024 | -225,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2023 | -1.06 Mn |